D. Abernethy, D. Greenblatt, M. Divoll, R. Arendt, H. Ochs et al., Impairment of Diazepam Metabolism by Low-Dose Estrogen-Containing Oral-Contraceptive Steroids, New England Journal of Medicine, vol.306, issue.13, pp.791-793, 1982.
DOI : 10.1056/NEJM198204013061307

H. Abou-auda, M. Al-yamani, and R. Abou-shaaban, A new accurate method for predicting lithium clearance and daily dosage requirements in adult psychiatric patients, Bipolar Disorders, vol.26, issue.4, pp.369-76, 2008.
DOI : 10.1111/j.1600-0447.1997.tb09646.x

M. Alda, Pharmacogenetics of lithium response in bipolar disorder, J. Psychiatry Neurosci, vol.24, issue.2, pp.154-158, 1999.

J. Allen, P. Rack, and K. Vaddadi, Differences of the effects of clomipramine on English and Asian volunteers.Preliminary report on a pilot study, Post-grad Med J, vol.53, issue.4, pp.79-86, 1977.

C. Arbus, A. Benyamina, P. Llorca, F. Baylé, N. Bromet et al., Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine, European Journal of Pharmaceutical Sciences, vol.32, issue.4-5, pp.4-5357, 2007.
DOI : 10.1016/j.ejps.2007.09.003

M. Arranz, D. Collier, M. Sodhi, D. Ball, G. Roberts et al., Association between clozapine response and allelic variation in 5-HT2A receptor gene, The Lancet, vol.346, issue.8970, pp.281-283, 1995.
DOI : 10.1016/S0140-6736(95)92168-0

M. J. Arranz, D. A. Collier, J. Munro, P. Sham, G. Kirov et al., Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine, Neuroscience Letters, vol.217, issue.2-3, pp.177-185, 1996.
DOI : 10.1016/0304-3940(96)13094-9

M. J. Arranz, T. Li, J. Munro, X. Liu, R. Murray et al., Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response, Pharmacogenetics, vol.8, issue.6, pp.481-485, 1998.
DOI : 10.1097/00008571-199812000-00004

M. J. Arranz, J. Munro, J. Birkett, A. Bolonna, D. Mancama et al., Pharmacogenetic prediction of clozapine response, The Lancet, vol.355, issue.9215, pp.1615-1621, 2000.
DOI : 10.1016/S0140-6736(00)02221-2

M. J. Arranz, J. Munro, M. J. Owen, G. Spurlock, P. C. Sham et al., Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine, Molecular Psychiatry, vol.3, issue.1, pp.61-67, 1998.
DOI : 10.1038/sj.mp.4000348

M. J. Arranz, J. Munro, P. Sham, G. Kirov, R. M. Murray et al., Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response, Schizophrenia Research, vol.32, issue.2, pp.93-102, 1998.
DOI : 10.1016/S0920-9964(98)00032-2

M. J. Arranz, J. Munro, S. Osborne, D. Collier, and R. W. Kerwin, Applications of pharmacogenetics in psychiatry: personalisation of treatment, Expert Opinion on Pharmacotherapy, vol.217, issue.6, pp.537-542, 2001.
DOI : 10.1517/14656566.2.4.537

. Benedetti, . Serretti, . Pondiggia, . Bernasconi, . Lorenzi et al., Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-?? ???50 T/C SNP, Neuroscience Letters, vol.376, issue.1, pp.51-55, 2005.
DOI : 10.1016/j.neulet.2004.11.022

D. Benmessaoud, N. Hamdani, C. Boni, N. Ramoz, M. Hamon et al., Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2Areceptor gene in patients with schizophrenia responsive to antipsychotics, BMC Psychiatry, vol.12, issue.suppl.44, p.40, 2008.
DOI : 10.1017/S1092852900020903

S. Bernard, K. Neville, A. Nguyen, and D. Flockhart, Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications, The Oncologist, vol.11, issue.2, pp.126-161, 2006.
DOI : 10.1634/theoncologist.11-2-126

M. Berridge and R. Irvine, Inositol phosphates and cell signalling, Nature, vol.341, issue.6239, pp.197-205, 1989.
DOI : 10.1038/341197a0

L. Bertilsson, M. Dahl, P. Dalén, and A. , Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs, British Journal of Clinical Pharmacology, vol.10, issue.2, pp.53-111, 2002.
DOI : 10.1046/j.0306-5251.2001.01548.x

J. Bidart and L. Lacroix, Puces à ADN. Méthodes d'étude du génôme et du transcriptome. Méthode d'étude en biologie moléculaire, chapitre 24, pp.372-384

R. Binder and R. Levy, Extrapyramidal reactions in Asians, Am J Psychiatry, vol.138, issue.9, pp.1243-1247, 1981.

B. Bondy and P. , Pharmacogenetics and psychopharmacology, Current Opinion in Pharmacology, vol.4, issue.1, pp.72-78, 2004.
DOI : 10.1016/j.coph.2003.09.007

M. Bourel and R. Ardaillou, Pharmacogénétique et pharmacogénomique, Bull. Acad. Natle. Med, vol.1, pp.9-24, 0190.

A. J. Brookes, The essence of SNPs, Gene, vol.234, issue.2, pp.177-86, 1999.
DOI : 10.1016/S0378-1119(99)00219-X

R. Bunzel, I. Blumcke, S. Cichon, S. Normann, J. Schramm et al., Polymorphic imprinting of the serotonin-2A (5-HT2A) receptor gene in human adult brain, Molecular Brain Research, vol.59, issue.1, pp.90-92, 1998.
DOI : 10.1016/S0169-328X(98)00146-6

M. Butler, N. Lang, J. Young, N. Caporason, P. Vineis et al., Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites, Pharmacogenetics, vol.2, issue.3, pp.116-127, 1992.
DOI : 10.1097/00008571-199206000-00003

J. P. Chen, K. M. Lin, and H. Chung, Prescribing medication for Asians with mental disorders, West. J. Med, vol.176, pp.271-275, 2002.

J. M. Coly, ethnie : une histoire complexe, Encyclopedia Universalis France SA, 2002.

E. Corruble and P. Hardy, Observance du traitement en psychiatrie. Encyclopédie médico-chirurgicale, Psychiatrie, 37-860-A-60, p.6, 2003.

S. Cross and D. Bhugra, Management and culture ??? psychopharmacology, Psychiatry, vol.8, issue.9, pp.365-367, 2009.
DOI : 10.1016/j.mppsy.2009.06.004

D. Dai, J. Tang, R. Rose, E. Hodgson, R. Bienstock et al., Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos, J Pharmacol Exp Ther, 2001.

P. Dalén, M. Dahl, M. Eichelbaum, L. Bertilsson, and G. Wilkinson, Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes, Pharmacogenetics and Genomics, vol.9, issue.6, pp.697-706, 1999.
DOI : 10.1097/01213011-199912000-00004

S. Davis and D. Nutt, Pharmacokinetics for psychiatrists, Psychiatry, vol.6, issue.7, pp.268-72, 2007.
DOI : 10.1016/j.mppsy.2007.04.003

Z. Desta, X. Zhao, J. Shin, and D. Flockhart, Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism, Clinical Pharmacokinetics, vol.32, issue.4, pp.913-58, 2002.
DOI : 10.2165/00003088-200241120-00002

V. Dolzan, A. Serretti, L. Mandelli, J. Koprivsek, M. Kastelic et al., Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes, Prog Neuropsychopharmacol Biol Psychiatry, vol.132, issue.6, pp.1562-1568, 2008.

J. Dorne, K. Walton, W. Slob, and A. G. Renwick, Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food and chemical toxicology, pp.40-1633, 2002.

J. Du, Y. Xu, S. Duan, A. Zhang, J. Xuan et al., A case???control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population, Progress in neuro-psychopharmacology and biological psychiatry, pp.33-1200, 2009.
DOI : 10.1016/j.pnpbp.2009.06.023

M. Eichelbaum, M. Ingelman-sundberg, and W. Evans, Pharmacogenomics and Individualized Drug Therapy, Annual Review of Medicine, vol.57, issue.1, pp.119-137, 2006.
DOI : 10.1146/annurev.med.56.082103.104724

R. Eiselt, T. Domanski, A. Zibat, R. Mueller, E. Presecan-siedel et al., Identification and functional characterization of eight CYP3A4 protein variants, Pharmacogenetics, vol.11, issue.5, pp.447-58, 2001.
DOI : 10.1097/00008571-200107000-00008

V. L. Ellingrod, B. C. Lund, D. Miller, F. Fleming, P. Perry et al., 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia, Psychopharmacol. Bull, vol.37, issue.2, pp.109-121, 2003.

W. Evans and M. Relling, Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics, Science, vol.286, issue.5439, pp.487-491, 1999.
DOI : 10.1126/science.286.5439.487

C. Finta and P. Zaphiropoulos, The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons, Gene, vol.260, issue.1-2, pp.13-23, 2000.
DOI : 10.1016/S0378-1119(00)00470-4

M. Floyd, G. Gervasini, A. Masica, G. Mayo, A. George et al., Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women, Pharmacogenetics, vol.13, issue.10, 2003.
DOI : 10.1097/00008571-200310000-00003

E. Frackiewicz, J. Sramek, J. Herrera, N. Kurtz, and N. Cutler, Ethnicity and Antipsychotic Response, Annals of Pharmacotherapy, vol.27, issue.11, pp.1360-1369, 1997.
DOI : 10.1016/S0140-6736(77)91430-1

N. Franck, F. Et, and . Thibaut, Pharmacologie et mode d???action des neuroleptiques, EMC - Psychiatrie, vol.2, issue.4, pp.282-299, 2005.
DOI : 10.1016/j.emcps.2005.01.001

D. Frank, U. Jaehde, and U. Fuhr, Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping, European Journal of Clinical Pharmacology, vol.76, issue.4, pp.321-354, 2007.
DOI : 10.1007/s00228-006-0250-8

H. Fraser, J. Mucklow, C. Bulpitt, C. Kahn, G. Mould et al., Environmental factors affecting antipyrine metabolism in London factory and office workers., British Journal of Clinical Pharmacology, vol.18, issue.3, pp.237-243, 1979.
DOI : 10.1111/j.1365-2125.1979.tb00928.x

R. Frye, G. Matzke, A. Adedoyin, J. Porter, and R. Branch, Validation of the five-drug ???Pittsburgh cocktail??? approach for assessment of selective regulation of drug-metabolizing enzymes*, Clinical Pharmacology & Therapeutics, vol.33, issue.4, pp.365-376, 1997.
DOI : 10.1016/S0009-9236(97)90114-4

N. Ftouhi-paquin, A. M. Grof, P. Chretien, N. Rouleau, G. Turecki et al., Identification of three polymorphisms in the translated region of PLC-?1 and their investigation in lithium responsive bipolar disorder, American Journal of Medical Genetics, vol.3, issue.3, pp.301-306, 2001.
DOI : 10.1002/ajmg.1326

R. Fux, K. Mörike, A. Pröhmer, U. Delabar, M. Schwab et al., Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study, Clinical Pharmacology & Therapeutics, vol.78, issue.4, pp.378-87, 2005.
DOI : 10.1016/j.clpt.2005.07.004

A. Gaedigk, L. Ndjountché, K. Divakaran, D. Bradford, L. Zineh et al., Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events, Clinical Pharmacology & Therapeutics, vol.4, issue.2, 2007.
DOI : 10.1038/sj.clpt.6100033

A. Gaw, Culture, ethnicity and mental illness, pp.245-280, 1992.

K. Gellner, R. Eiselt, E. Hustert, H. Arnold, I. Koch et al., Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene, Pharmacogenetics, vol.11, issue.2, 2001.
DOI : 10.1097/00008571-200103000-00002

M. M. Ghoneim, K. Korttila, and C. K. Chiang, Diazepam effects and kinetics in Caucasians and Orientals, Clinical Pharmacology and Therapeutics, vol.29, issue.6, pp.749-756, 1981.
DOI : 10.1038/clpt.1981.106

J. Goldstein, Gender difference in the course of schizophrenia, American Journal of Psychiatry, vol.145, pp.684-689, 1998.

P. Gorwood and N. Hamdani, Apport de la génétique aux traitements psychiatriques. La presse médicale, pp.902-906, 2008.

N. Hamdani, M. Bonniere, J. Ades, M. Hamon, C. Boni et al., Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics, Neuroscience Letters, vol.377, issue.1, pp.69-74, 2005.
DOI : 10.1016/j.neulet.2004.11.070

. Beaune, Human cytochromes P450, Molecular aspects of Medicine, vol.20, pp.1-137, 1999.
URL : https://hal.archives-ouvertes.fr/hal-00466852

L. A. Hazelwood and E. Sanders-bush, His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation, Mol. Pharmacol, vol.66, issue.5, pp.1293-300, 2004.

A. Heils, A. Teufel, S. Petri, G. Stober, P. Riederer et al., Allelic Variation of Human Serotonin Transporter Gene Expression, Journal of Neurochemistry, vol.66, issue.6, pp.2621-2625, 1996.
DOI : 10.1046/j.1471-4159.1996.66062621.x

H. Herken, M. E. Erdal, K. Esgi, O. Virit, and A. S. Aynacioglu, The relationship between the response to risperidone treatment and HT2A receptor gene (T102C and 1438G/A) polymorphism in schizophrenia, Bull. Clin. Psychopharmacol, vol.13, pp.161-167, 2003.

K. Herrlin, N. Yasui-furukori, G. Tybring, J. Widén, L. Gustafsson et al., Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes, British Journal of Clinical Pharmacology, vol.51, issue.Suppl 5, pp.415-436, 2003.
DOI : 10.1046/j.1365-2125.2003.01874.x

T. Hirota, I. Ieiri, H. Takane, S. Maegawa, M. Hosokawa et al., Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status, Human Molecular Genetics, vol.13, issue.23, pp.2959-69, 2001.
DOI : 10.1093/hmg/ddh313

Y. Horai, M. Nakano, T. Ishizaki, K. Ishikawa, H. H. Zhou et al., Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese, Clinical Pharmacology and Therapeutics, vol.46, issue.2, pp.198-207, 1989.
DOI : 10.1038/clpt.1989.126

R. Hwang, T. Shinkai, V. De-luca, D. J. Muller, X. Ni et al., Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations, Psychopharmacology, vol.61, issue.1, p.14, 2005.
DOI : 10.1007/s00213-005-2223-5

A. Illi, K. M. Mattila, O. Kampman, S. Anttila, M. Roivas et al., Catechol-O-methyltransferase and Monoamine Oxidase A Genotypes and Drug Response to Conventional Neuroleptics in Schizophrenia, Journal of Clinical Psychopharmacology, vol.23, issue.5, pp.429-463, 2003.
DOI : 10.1097/01.jcp.0000088916.02635.33

M. Ingelman-sundberg, M. Oscarson, and R. Mclellan, Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment, Trends in Pharmacological Sciences, vol.20, issue.8, pp.342-349, 1999.
DOI : 10.1016/S0165-6147(99)01363-2

M. Ingelman-sundberg, S. C. Sim, A. Gomez, and C. Rodriguez-antona, Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects, Pharmacology & Therapeutics, vol.116, issue.3, pp.496-526, 2007.
DOI : 10.1016/j.pharmthera.2007.09.004

M. Ingelman-sundberg and S. C. Sim, Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system, Biochemical and Biophysical Research Communications, vol.396, issue.1, pp.90-94, 2010.
DOI : 10.1016/j.bbrc.2010.02.162

M. Ingelman-sundberg, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity, The Pharmacogenomics Journal, vol.5, issue.1, pp.6-13, 2005.
DOI : 10.1038/sj.tpj.6500285

M. Ingelman-sundberg, Pharmacogenetics of CYP450 and its applications in drug therapy: the past, present and future, Trends in pharmacological sciences, vol.25, pp.4-193, 2004.

P. Jaanson, T. Marandi, R. Kiivet, V. Vasar, S. Vään et al., Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype, Psychopharmacology, vol.162, issue.1, pp.67-73, 2002.
DOI : 10.1007/s00213-002-1059-5

E. Jonsson, M. M. Nothen, R. Bunzel, P. Propping, and G. Sedvall, 5HT2a receptor T102C polymorphism and schizophrenia, Lancet, vol.347, issue.9018, p.1831, 1996.

E. G. Jonsson, M. M. Nothen, F. Grunhage, L. Farde, Y. Nakashima et al., Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers, Molecular Psychiatry, vol.4, issue.3, pp.290-296, 1999.
DOI : 10.1038/sj.mp.4000532

R. Joober, C. Benkelfat, K. Brisebois, A. Toulouse, G. Turecki et al., T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability, J. Psychiatry Neurosci, vol.24, issue.2, pp.141-147, 1999.

S. C. Jose-de-leon, K. L. Armstrong, and . Cozza, Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19, Psychosomatics, vol.47, issue.1, pp.75-85, 2006.
DOI : 10.1176/appi.psy.47.1.75

S. C. Jose-de-leon, K. L. Armstrong, and . Cozza, The Dosing of Atypical Antipsychotics, Psychosomatics, vol.46, issue.3, pp.262-273, 2005.
DOI : 10.1176/appi.psy.46.3.262

R. Kaiser, O. Sezer, A. Papies, S. Bauer, C. Schelenz et al., Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes, Journal of Clinical Oncology, vol.20, issue.12, pp.2805-2816, 2002.
DOI : 10.1200/JCO.2002.09.064

C. Kawanishi, S. Lundgren, H. Agren, and L. Bertilsson, Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study, Eur J Clin Pharmacol, vol.59, issue.11, pp.803-810, 2004.

S. N. Kelada, P. Costa-mallen, H. Checkoway, C. S. Carlson, T. S. Weller et al., Dopamine transporter (SLC6A3) 5??? region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson??s disease, Pharmacogenetics and Genomics, vol.15, issue.9, pp.659-68, 2005.
DOI : 10.1097/01.fpc.0000170917.04275.d6

J. Kim, C. Lee, H. Kim, Y. Jo, J. Lee et al., The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women, Oncol Rep, vol.22, issue.3, pp.487-92, 2009.

S. Kimmel, L. Gonsalves, D. Youngs, and G. Guidwani, Fluctuating levels of antidepressants premenstrually, Journal of Psychosomatic Obstetrics & Gynecology, vol.26, issue.33, pp.277-280, 1992.
DOI : 10.3109/01674829209009200

J. Kirchheiner, K. Nickchen, M. Bauer, M. Wong, J. Licinio et al., Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Molecular Psychiatry, vol.9, issue.5, 2004.
DOI : 10.1038/sj.mp.4001494

J. Kirchheiner, H. Schmidt, M. Tzvetkov, J. Keulen, J. Lötsch et al., Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication, The Pharmacogenomics Journal, vol.54, issue.4, pp.257-65, 2007.
DOI : 10.1074/jbc.M402337200

U. Klotz, Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem, Int. Journal of Clinical Pharmacology and Therapeutics, vol.44, issue.07, pp.297-302, 2006.
DOI : 10.5414/CPP44297

G. Koren, J. Cairns, D. Chitayat, A. Gaedigk, and S. Leeder, Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother, The Lancet, vol.368, issue.9536, p.704, 2006.
DOI : 10.1016/S0140-6736(06)69255-6

P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, pp.383-91, 2001.
DOI : 10.1038/86882

A. Küpfer and R. Preisig, Inherited Defects of Hepatic Drug Metabolism, Seminars in Liver Disease, vol.3, issue.04, pp.341-54, 1983.
DOI : 10.1055/s-2008-1040786

A. Laakso, T. Pohjalainen, J. Bergman, J. Kajander, M. Haaparanta et al., The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects, Pharmacogenetics and Genomics, vol.15, issue.6, pp.387-91, 2005.
DOI : 10.1097/01213011-200506000-00003

H. M. Lachman, D. F. Papolos, T. Saito, Y. M. Yu, C. L. Szumlanski et al., Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders, Pharmacogenetics, vol.6, issue.3, pp.243-50, 1996.
DOI : 10.1097/00008571-199606000-00007

D. Lacroix, M. Sonnier, A. Moncion, G. Cheron, and T. Cresteil, Expression of CYP3A in the Human Liver - Evidence that the Shift between CYP3A7 and CYP3A4 Occurs Immediately After Birth, European Journal of Biochemistry, vol.34, issue.2, pp.625-659, 1997.
DOI : 10.1006/bbrc.1993.1803

M. Landi, R. Sinha, N. Lang, and F. Kadlubar, Human cytochrome P4501A2, IARC Sci Publ, issue.148, pp.173-95, 1999.

J. Lappalainen, L. Zhang, M. Dean, M. Oz, N. Ozaki et al., Identification, Expression, and Pharmacology of a Cys23-Ser23 Substitution in the Human 5-HT2C Receptor Gene (HTR2C), Genomics, vol.27, issue.2, pp.274-283, 1995.
DOI : 10.1006/geno.1995.1042

T. Lencz, D. G. Robinson, K. Xu, J. Ekholm, S. Sevy et al., DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients, American Journal of Psychiatry, vol.163, issue.3, pp.529-560, 2006.
DOI : 10.1176/appi.ajp.163.3.529

K. P. Lesch and L. Gutknecht, Pharmacogenetics of the serotonin transporter, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.29, issue.6, pp.1062-73, 2005.
DOI : 10.1016/j.pnpbp.2005.03.012

J. A. Lieberman, Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia, Journal of Clinical Psychiatry, vol.60, pp.9-12, 1999.

J. A. Lieberman, A. R. Koreen, M. Chakos, B. Sheitman, M. Woerner et al., Factors influencing treatment response and outcome of first episode schizophrenia: implications for understanding the pathophysiology of schizophrenia, Journal of Clinical Psychiatry, vol.57, pp.5-9, 1996.

C. H. Lin, S. J. Tsai, Y. W. Yu, H. L. Song, P. C. Tu et al., No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population, NeuroReport, vol.10, issue.1, pp.57-60, 1999.
DOI : 10.1097/00001756-199901180-00011

K. Lin and E. Finder, Neuroleptic dosage for Asians, Am J Psychiatry, vol.140, issue.4, pp.490-491, 1983.

K. Lin, R. Poland, I. Nuccio, K. Matsuda, N. Hathuc et al., A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients, Am J Psychiatry. Oct, vol.146, issue.10, pp.1307-1318, 1989.

K. Lin and F. Cheung, Mental Health Issues for Asian Americans, Psychiatric Services, vol.50, issue.6, pp.774-780, 1999.
DOI : 10.1176/ps.50.6.774

K. M. Lin, R. E. Poland, J. K. Lau, and R. T. Rubin, Haloperidol and Prolactin Concentrations in Asians and Caucasians, Journal of Clinical Psychopharmacology, vol.8, issue.3, pp.195-201, 1998.
DOI : 10.1097/00004714-198806000-00008

P. Lin and N. , A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients, American Journal of psychiatry, vol.146, pp.1307-1311, 1989.

P. Llorca, C. Lancon, B. Disdier, J. Farisse, C. Sapin et al., Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations, J. Psychiatry Neurosci, vol.27, issue.1, pp.30-37, 2002.

A. D. Loebel, J. A. Lieberman, J. M. Alvir, D. I. Mayerhoff, S. Geisler et al., Duration of untreated psychosis and outcome in first episode schizophrenia, American Journal of Psychiatry, vol.149, pp.1183-1188, 1992.

R. Lovlie, J. Berle, E. Stordal, and V. Steen, The phospholipase C-??1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism, Psychiatric Genetics, vol.11, issue.1, pp.41-44, 2001.
DOI : 10.1097/00041444-200103000-00008

M. Ma, M. Woo, and H. Mcleod, Genetic basis of drug metabolism, Am. J. Health Syst. Pharm, vol.59, pp.2061-2069, 2002.

. Maekawa, CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug metabolism and disposition, pp.2100-2104, 2010.

A. K. Malhotra, D. Goldman, N. Ozaki, W. Rooney, A. Clifton et al., Clozapine response and the 5HT2C Cys23Ser polymorphism, NeuroReport, vol.7, issue.13, pp.2100-2102, 1996.
DOI : 10.1097/00001756-199609020-00007

M. Marshall, S. Lewis, A. Lockwood, R. Drake, P. Jones et al., Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients, Archives of General Psychiatry, vol.62, issue.9, pp.975-983, 2005.
DOI : 10.1001/archpsyc.62.9.975

M. Masellis, V. Basile, H. Y. Meltzer, J. A. Lieberman, S. Sevy et al., Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients, Neuropsychopharmacology, vol.19, issue.2, pp.123-155, 1998.
DOI : 10.1016/S0893-133X(98)00007-4

M. Masellis, A. D. Paterson, F. Badri, J. A. Lieberman, H. Y. Meltzer et al., Genetic variation of 5-HT2A receptor and response to clozapine, The Lancet, vol.346, issue.8982, p.1108, 1995.
DOI : 10.1016/S0140-6736(95)91785-3

I. Mata-pastor, M. J. Arranz-calderon, M. Beperet-urmeneta, F. Perez-nievas, P. Sham et al., Influence of serotonergic transmission on response to olanzapine, Actas. Esp. Psiquiatr, vol.30, issue.5, pp.265-71, 2002.

M. Glashan and T. H. , Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course?, Biological Psychiatry, vol.46, issue.7, pp.899-907, 1999.
DOI : 10.1016/S0006-3223(99)00084-0

T. H. Mc-glashan, The Prediction of Outcome in Chronic Schizophrenia, Archives of General Psychiatry, vol.43, issue.2, pp.167-176, 1986.
DOI : 10.1001/archpsyc.1986.01800020077010

M. Michelon, . Cordeiro, . Miguita, . Breen, . Collier et al., Association study of the INPP1, 5HTT, BDNF, AP-2?? and GSK-3?? GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder, Neuroscience Letters, vol.403, issue.3, pp.288-293, 2006.
DOI : 10.1016/j.neulet.2006.05.001

K. Mihara, A. Suzuki, T. Kondo, N. Yasui, H. Furukori et al., Effects of the allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia, Clinical Pharmacology & Therapeutics, vol.65, issue.3, pp.291-295, 1999.
DOI : 10.1016/S0009-9236(99)70108-6

Y. Mitsunaga, T. Kubota, A. Ishiguro, Y. Yamada, I. Sasaki et al., Frequent occurrence of CYP2D6???10 duplication allele in a Japanese population, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.505, issue.1-2, pp.505-83, 2002.
DOI : 10.1016/S0027-5107(02)00122-7

S. Morita, K. Shimoda, T. Someya, Y. Yoshimura, K. Kamijima et al., Steady-State Plasma Levels of Nortriptyline and Its Hydroxylated Metabolites in Japanese Patients: Impact of CYP2D6 Genotype on the Hydroxylation of Nortriptyline, Journal of Clinical Psychopharmacology, vol.20, issue.2, pp.141-150, 2000.
DOI : 10.1097/00004714-200004000-00005

E. Mornet, Méthodes d'analyse de l'ADN, applications médicales et médicolégales

H. Mulder, E. Heerdink, V. Iersel, E. Wilmink, F. Egberts et al., Prevalence of Patients Using Drugs Metabolized by Cytochrome P450 2D6 in Different Populations: a Cross-Sectional Study, Annals of Pharmacotherapy, vol.41, issue.3, pp.408-421, 2007.
DOI : 10.1345/aph.1H482

M. Murray, Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents, Journal of Pharmacy and Pharmacology, vol.369, issue.Suppl. 1, pp.871-885, 2006.
DOI : 10.1211/jpp.58.7.0001

M. Nakajima, T. Yokoi, M. Mizutani, S. Shin, F. Kadlubar et al., Phenotyping of CYP1A2 in Japanese populations by analysis of caffeine urinary metabolites: absence of mutation presecribing the phenotype in the CYP1A2 gene, Cancer Epidemiol. Biomarkers Prev, vol.3, pp.413-421, 1994.

T. Nakamura, Y. Saito, N. Murayama, M. Saeki, A. Soyama et al., Apparent Low Frequency of Sequence Variability within the Proximal Promoter Region of the Cytochrome P450 (CYP) 3A5 Gene in Established Cell Lines from Japanese Individuals., Biological & Pharmaceutical Bulletin, vol.24, issue.8, pp.954-961, 2001.
DOI : 10.1248/bpb.24.954

F. Navarro, J. Van-os, P. Jones, and R. Murray, Explaining sex differences in course and outcome in the functional psychoses, Schizophrenia Research, vol.21, issue.3, pp.161-170, 1996.
DOI : 10.1016/0920-9964(96)00032-1

V. L. Nimgaonkar, X. R. Zhang, J. S. Brar, M. Deleo, and R. Ganguli, 5-HT2 receptor gene locus, Psychiatric Genetics, vol.6, issue.1, pp.23-27, 1996.
DOI : 10.1097/00041444-199621000-00005

M. M. Nothen, M. Rietschel, J. Erdmann, H. Oberlander, H. J. Moller et al., Genetic variation of the 5-HT2A receptor and response to clozapine, The Lancet, vol.346, issue.8979, pp.908-917, 1995.
DOI : 10.1016/S0140-6736(95)92756-5

. Oi-yin, J. Wong, S. Leung, T. Mak, R. Man-kin et al., Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Neuro- Psychopharmacology and biological psychiatry, pp.30-251, 2006.

V. Ozdemir, W. Kalow, B. Tang, A. Paterson, S. Walker et al., Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method, Pharmacogenetics, 2000.

P. Beaune, Les cytochromes P450 humains. Applications en pharmacologie, Thérapie, vol.48, pp.521-526, 1993.

M. J. Parsons, U. M. Souza, M. J. Arranz, R. W. Kerwin, and A. J. Makoff, The ???1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity, Biological Psychiatry, vol.56, issue.6, pp.406-416, 2004.
DOI : 10.1016/j.biopsych.2004.06.020

D. O. Perkins, H. Gu, K. Boteva, and J. A. Lieberman, Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis, American Journal of Psychiatry, vol.162, issue.10, pp.1785-1804, 2005.
DOI : 10.1176/appi.ajp.162.10.1785

E. Pi and G. M. Simpson, Psychopharmacology: Cross-Cultural Psychopharmacology: A Current Clinical Perspective, Psychiatric Services, vol.56, issue.1, pp.31-33, 2005.
DOI : 10.1176/appi.ps.56.1.31

E. H. Pi, . Simpson-gm, and T. B. Cooper, Pharmacokinetics of desipramine in Caucasian and Asian volunteers, Am. J. Psychiatry, vol.143, pp.1174-1176, 1986.

T. Pohjalainen, J. O. Rinne, K. Nagren, P. Lehikoinen, K. Anttila et al., The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers, Molecular Psychiatry, vol.3, issue.3, pp.256-60, 1998.
DOI : 10.1038/sj.mp.4000350

R. Poland, K. Lin, C. Nuccio, and G. Wilkinson, Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans*, Clinical Pharmacology & Therapeutics, vol.72, issue.3, pp.288-93, 2002.
DOI : 10.1067/mcp.2002.127398

B. Pollock, Recent Developments in Drug Metabolism of Relevance to Psychiatrists, Harvard Review of Psychiatry, vol.2, issue.4, pp.204-213, 1994.
DOI : 10.3109/10673229409017138

B. Pollock, The endocrine treatment interface: gender differences in psychotropic drug metabolism, Psychopharmacology Bulletin, vol.33, pp.235-241, 1997.

S. Potkin, Y. Shen, H. Pardes, B. Phelps, D. Zhou et al., Haloperidol concentrations elevated in Chinese patients, Psychiatry Research, vol.12, issue.2, 1984.
DOI : 10.1016/0165-1781(84)90017-9

T. Prior, P. Chue, P. Tibbo, and G. B. Baker, Drug metabolism and atypical antipsychotics, European Neuropsychopharmacology, vol.9, issue.4, pp.301-309, 1999.
DOI : 10.1016/S0924-977X(98)00040-6

T. Rau, G. Wohlleben, H. Wuttke, N. Thuerauf, J. Lunkenheimer et al., Cyp2d6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants???a pilot study, Clinical Pharmacology & Therapeutics, vol.75, issue.5, 2004.
DOI : 10.1016/j.clpt.2003.12.015

G. P. Reynolds, L. A. Templeman, and Z. J. Zhang, The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.29, issue.6, pp.1021-1029, 2005.
DOI : 10.1016/j.pnpbp.2005.03.019

D. G. Robinson, M. G. Woermer, J. M. Alvir, S. Geisler, A. Koreen et al., Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder, American Journal of Psychiatry, vol.156, pp.544-549, 1999.

C. Rodríguez-antona, M. Jande, A. Rane, and M. Ingelman-sundberg, Identification and phenotype characterization of two haplotypes causing different enzymatic capacity in fetal livers, Clinical Pharmacology & Therapeutics, vol.77, issue.4, pp.259-70, 2005.
DOI : 10.1016/j.clpt.2004.11.003

H. Roh, J. Chung, D. Oh, C. Park, J. Svensson et al., Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients, British Journal of Clinical Pharmacology, vol.54, issue.3, pp.265-71, 2001.
DOI : 10.1046/j.0306-5251.2001.01437.x

B. Rouleau, P. Vincent, and J. Martel, Le monitorage thérapeutique de la clozapine : une nécessité clinique, Pharmactuel, vol.41, issue.2, pp.87-93, 2008.

C. Samer, . Desmeules, . Rossier, and D. Hochstrasser, Le polymorphisme génétique du CYP450 2D6 : le bon, l'ultrarapide, l'intermédiaire et le lent

M. Schafer, D. Rujescu, I. Giegling, A. Guntermann, A. Erfurth et al., Receptor Gene, American Journal of Psychiatry, vol.158, issue.5, pp.802-806, 2001.
DOI : 10.1176/appi.ajp.158.5.802

J. Schumacher, T. G. Schulze, T. F. Wienker, M. Rietschel, and M. M. Nothen, Pharmacogenetics of clozapine response, The Lancet, vol.356, issue.9228, pp.506-513, 2000.
DOI : 10.1016/S0140-6736(05)74176-3

J. Senon, D. Sechter, and D. Richard, Thérapeutique psychiatrique. Ouvrage publié en 1995. Hermann Editeurs des sciences et des arts

M. Shams, B. Arneth, C. Hiemke, A. Dragicevic, M. Müller et al., CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine, Journal of Clinical Pharmacy and Therapeutics, vol.17, issue.5, pp.493-502, 2006.
DOI : 10.1002/gps.591

N. Shinfuku and C. Tan, Pharmacotherapy for schizophrenic inpatients in East Asia ??? Changes and challenges, International Review of Psychiatry, vol.60, issue.6, 2008.
DOI : 10.1080/09540260802397560

K. Sim, H. C. Su, S. Fujii, S. Yang, M. Chong et al., High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies, Research on East Asia Psychotropic Prescription (REAP) studies, pp.110-117, 2001.
DOI : 10.1111/j.1365-2125.2008.03304.x

K. Sim, T. H. Chua, Y. H. Chan, R. Mahendran, and S. A. Chong, Psychiatric comorbidity in first episode schizophrenia: A 2 year, longitudinal outcome study???, Journal of Psychiatric Research, vol.40, issue.7, pp.656-663, 2006.
DOI : 10.1016/j.jpsychires.2006.06.008

U. Stamer and F. Stüber, The pharmacogenetics of analgesia, Expert Opinion on Pharmacotherapy, vol.94, issue.14, pp.2235-2280, 2007.
DOI : 10.1136/jmg.2004.027698

L. Steen, . Osher, . Belmaker, . Berle, and . Gulbrandsen, The polymorphic inositol polyphosphate-1 phosphatase gene as a candidate for pharmacogenetic prediction of lithium responsive manic-depressive illness, Pharmacogenetics, vol.8, pp.259-268, 1998.

W. Steimer, K. Zöpf, S. Von-amelunxen, H. Pfeiffer, J. Bachofer et al., Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy, Clinical Chemistry, vol.51, issue.2, 2005.
DOI : 10.1373/clinchem.2004.041327

. Huak, Metabolic differences between Asian and Caucasian patients on clozapine treatment, Human Psychopharmacology Clin Exp, vol.22, pp.217-222, 2007.

A. Suzuki, K. Mihara, T. Kondo, O. Tanaka, U. Nagashima et al., The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients, Pharmacogenetics, vol.10, issue.4, pp.335-376, 2000.
DOI : 10.1097/00008571-200006000-00007

M. Szaflarski, J. Szaflarski, M. Privitera, D. Ficker, and R. Horner, Racial/ethnic disparities in the treatment of epilepsy: What do we know? What do we need to know?, Epilepsy & Behavior, vol.9, issue.2, pp.243-264, 2006.
DOI : 10.1016/j.yebeh.2006.05.011

G. Szekeres, S. Keri, A. Juhasz, A. Rimanoczy, I. Szendi et al., Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol.3, issue.1, pp.1-5, 2004.
DOI : 10.1002/ajmg.b.20045

I. Takashi, K. Motohiro, C. Koji, O. Osamu, and S. Yuichi, Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature, Drug metab. Pharmacokinet, vol.25, issue.3, pp.243-253, 2010.

L. Tan, J. Yu, Y. Sun, J. Ou, J. Song et al., The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients, Clinical Neurology and Neurosurgery, vol.112, issue.4, pp.320-323, 2010.
DOI : 10.1016/j.clineuro.2010.01.002

T. Tateishi, Analysis of the CYP2D6 gene in relation to its metabolic capacity in Japanese men and in comparison with other populations, International Congress Series, vol.1244, pp.1244-1277, 2002.
DOI : 10.1016/S0531-5131(02)00454-5

T. Terao, K. Okuno, T. Okuno, H. Nakano, T. Shinkai et al., A Simpler and More Accurate Equation toPredict Daily Lithium Dose, Journal of Clinical Psychopharmacology, vol.19, issue.4, pp.336-340, 1999.
DOI : 10.1097/00004714-199908000-00009

G. Turecki, P. Grof, P. Cavazzoni, A. Duffy, E. Grof et al., Evidence for a role of phospholipase C-??1 in the pathogenesis of bipolar disorder, Molecular Psychiatry, vol.3, issue.6, pp.534-538, 1998.
DOI : 10.1038/sj.mp.4000447

D. S. Umbricht, W. C. Wirshing, D. A. Wirshing, M. Mcmeniman, N. R. Schooler et al., Clinical Predictors of Response to Clozapine Treatment in Ambulatory Patients With Schizophrenia, The Journal of Clinical Psychiatry, vol.63, issue.5, pp.420-424, 2002.
DOI : 10.4088/JCP.v63n0508

D. P. Van-kamen, M. E. Kelley, J. K. Yao, M. W. Gilberton, J. A. Gurklis et al., Predicting haloperidol treatment response in chronic schizophrenia, Psychiatry Research, vol.64, issue.1, pp.47-58, 1996.
DOI : 10.1016/0165-1781(96)02906-X

V. Ness, S. H. Owens, M. J. Kilts, and C. D. , The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density, BMC. Genet, vol.6, p.55, 2005.

J. Veenstra-vanderweele, G. M. Anderson, E. H. Cook, and . Jr, Pharmacogenetics and the serotonin system: initial studies and future directions, European Journal of Pharmacology, vol.410, issue.2-3, pp.165-181, 2000.
DOI : 10.1016/S0014-2999(00)00814-1

M. G. Hai, A. Petzold, M. Björkman, J. P. Ashton, and . Gil, and MDR1 in Vietnam, Eur J Clin Pharmacol, vol.65, pp.355-363, 2009.

L. Wang, L. Yu, G. He, J. Zhang, A. P. Zhang et al., Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients, Neuroscience Letters, vol.414, issue.1, pp.1-4, 2007.
DOI : 10.1016/j.neulet.2006.09.014

S. Wang, J. Huang, M. Lai, B. Liu, and M. Lai, Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6, Clinical Pharmacology and Therapeutics, vol.53, issue.4, pp.410-418, 1993.
DOI : 10.1038/clpt.1993.44

W. Bunney and B. L. Garland-bunney, Mecanisms of action of lithium in affective illness Basic and clinical applications : Psychopharmacology. The 3 rd generation of progress, pp.553-565, 1987.

G. Wilkinson, Drug Metabolism and Variability among Patients in Drug Response, New England Journal of Medicine, vol.352, issue.21, pp.2211-2232, 2005.
DOI : 10.1056/NEJMra032424

G. Wilkinson, F. Guengerich, and R. Branch, Genetic polymorphism of S-mephenytoin hydroxylation, Pharmacology & Therapeutics, vol.43, issue.1, pp.53-76, 1989.
DOI : 10.1016/0163-7258(89)90047-8

F. Wong and E. H. Pi, Ethnopsychopharmacology considerations for Asians and Asian Americans, Asian Journal of Psychiatry, vol.5, issue.1, pp.18-23, 2012.
DOI : 10.1016/j.ajp.2012.01.003

S. Wu, Q. Xing, R. Gao, X. Li, N. Gu et al., Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients, Neuroscience Letters, vol.376, issue.1, pp.1-4, 2004.
DOI : 10.1016/j.neulet.2004.11.014

Q. Xiang, X. Zhao, Y. Zhou, J. Duan, and Y. Cui, Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety, The Journal of Clinical Pharmacology, vol.36, issue.6, pp.659-666, 2010.
DOI : 10.1177/0091270009347867

H. Xie, S. Lundgren, U. Broberg, N. Finnström, A. Rane et al., Effect of cyclophosphamide on gene expression of cytochromes P450 and ??-actin in the HL-60 cell line, European Journal of Pharmacology, vol.449, issue.3, pp.197-205, 2002.
DOI : 10.1016/S0014-2999(02)01995-7

Q. Xing, X. Qian, H. Li, S. Wong, S. Wu et al., The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients, The International Journal of Neuropsychopharmacology, vol.10, issue.05, pp.1-7, 2006.
DOI : 10.1017/S146114570600719X

M. Xu, S. Li, Q. Xing, R. Gao, G. Feng et al., Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study, European Journal of Human Genetics, vol.28, issue.6, pp.707-712, 2010.
DOI : 10.1097/01.wnr.0000175245.58708.6b

J. Yamamoto, D. Fund, and S. Lo, Psychopharmacology for Asian Americans and Pacific Islanders, Psychopharmacol. Bull, vol.15, pp.29-31, 1979.

Y. Yamanouchi, N. Iwata, T. Suzuki, T. Kitajima, M. Ikeda et al., Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone, The Pharmacogenomics Journal, vol.3, issue.6, pp.356-61, 2003.
DOI : 10.1038/sj.tpj.6500211

Y. Yang, Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients, Acta Psychiatrica Scandinavica, vol.16, issue.2, pp.171-175, 1985.
DOI : 10.1111/j.1600-0447.1985.tb01267.x

S. Yasuda, L. Zhang, and S. Huang, The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies, Clinical Pharmacology & Therapeutics, vol.98, issue.3, pp.3-417, 2008.
DOI : 10.1038/clpt.2008.141

E. Yukawa, N. Nomiyama, S. Higuchi, and T. Aoyama, Lithium Population Pharmacokinetics from Routine Clinical Data, Therapeutic Drug Monitoring, vol.15, issue.2, pp.75-82, 1993.
DOI : 10.1097/00007691-199304000-00002

P. Zandi and J. Judy, The Promise and Reality of Pharmacogenetics in Psychiatry, Psychiatric Clinics of North America, vol.33, issue.1, pp.181-224, 2010.
DOI : 10.1016/j.psc.2009.12.001

U. Zanger, S. Raimundo, and M. Eichelbaum, Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.369, issue.1, pp.23-37, 2004.
DOI : 10.1007/s00210-003-0832-2

M. Zetin, D. Garber, D. Antonio, M. Schlegel, A. Feureisen et al., Prediction of lithium dose: A mathematical alternative to the test dose method, J Clin Psychiatry, vol.47, issue.20, pp.175-183, 1986.

J. Zhang-wong, M. Beiser, R. B. Zipursky, and G. Bean, An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol, Psychiatry Research, vol.81, issue.3, pp.333-339, 1998.
DOI : 10.1016/S0165-1781(98)00114-0

Z. Zhou, X. Li, H. Peng, X. Yu, M. Yang et al., Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia, Acta Pharmacologica Sinica, vol.23, issue.3, pp.381-386, 2006.
DOI : 10.1097/00004850-200503000-00002

J. Zhuge, Y. Luo, and Y. Yu, Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line déc-09 janv-11 mars-11 avr-11 juin-11 juil-11 aout 2011 sept-11 déc-11 mars-12 avr-12 11, World J Gastroenterol, vol.908, issue.1205, pp.2732-2738, 2003.

. Depoprodazone, Cyamemazine (Tercian®) (mg/j)

. Suppositoire-glycériné, Clozapine (Leponex®) (mg/j)

. Aripiprazole, Abilify®) (mg) Acide Valproique (Depakote®) (mg)